Treatment of acute myeloid leukemia (AML) largely depends on chemotherapy, but current regimens have been unsatisfactory for long-term remission. Although differentiation induction therapy utilizing 1,25(OH) 2 D 3 (VD3) has shown great promise for the improvement of AML treatment efficacy, severe side effects caused by its supraphysiological dose limit its clinical application. Here we investigated the combinatorial effect of L-asparaginase (ASNase)-mediated amino acid depletion and the latent alternation of VD3 activity on the induction of myeloid differentiation. ASNase treatment enhanced VD3-driven phenotypic and functional differentiation of three-different AML cell lines into monocyte/macrophages, along with c-Myc downregulation. Using gene silencing with shRNA and a chemical blocker, we found that reduced c-Myc is a critical factor for improving VD3 efficacy. c-Myc-dependent inhibition of mTORC1 signaling and induction of autophagy were involved in the enhanced AML cell differentiation. In addition, in a postculture of AML cells after each treatment, ASNase supports the antileukemic effect of VD3 by inhibiting cell growth and inducing apoptosis. Finally, we confirmed that the administration of ASNase significantly improved VD3 efficacy in the prolongation of survival time in mice bearing tumor xenograft. Our results are the first to demonstrate the extended application of ASNase, which is currently used for acute lymphoid leukemia, in VD3-mediated differentiation induction therapy for AML, and suggest that this drug combination may be a promising novel strategy for curing AML.
Acute myeloid leukemia (AML) is the most frequent type of leukemia, with cytogenetic heterogeneity. Despite advances in AML treatment, the classical chemoregimen from 1970, based on the combination of cytarabine and anthracyclines, remains unchanged. The initial remission rate following the chemoregimen is approximately 70% but majority of patients relapse early resulting in poor cure rate (<40%) with respect to long-term survival. 1 Therefore, there is a need to develop novel and effective therapeutics for AML.
Differentiation induction therapy is considered as a promising tool for the treatment of AML. Currently, all-trans retinoic acid (ATRA) is extensively used for treating AML, but this use is limited to acute promyelocytic leukemia (APL). 2 Although successful results for non-APL AML have been reported, ATRA efficacy is unsatisfactory under clinical settings. 3, 4 Another type of differentiation induction therapy is the induction of myeloid differentiation in AML cells by 1,25(OH) 2 D 3 (VD3), a hormonally active form of vitamin D. VD3 binding to its receptor, vitamin D receptor, leads to growth arrest and terminal differentiation of AML cells into monocyte/macrophage-like cells, resulting in the differentiation-associated apoptotic cell death in leukemic myeloblasts. [5] [6] [7] Although VD3 has quite an attractive effect on a broad range of AML in vitro, some adverse effects, such as the life threatening hypercalcemia provoked by use of supraphysiological doses of VD3 and the drug resistance caused by its single use, have limited its aggressive application in the clinic. [8] [9] [10] [11] To overcome these problems, numerous studies have focused on developing new VD3 analogs with reduced side effects 10, 12, 13 or identifying reagents that enhance VD3 efficacy [14] [15] [16] ; however, none of the agents have been successfully used in clinical applications. L-Asparaginase (ASNase), which catalyzes the degradation of L-asparagine (Asn) and glutamine (Gln), is the first enzyme drug actively used for patient with acute lymphoid leukemia (ALL). 17 Recently, there has been a growing interest in extending the therapeutic applications of ASNase-mediated amino acid deprivation to other malignant diseases because cancer cells require a large amount of amino acids to support their rapid growth. It has been found that the treatment of ASNase leads to apoptotic cell death through the inhibition of c-Myc and mTOR complex 1 (mTORC1) and through the induction of autophagy in AML cells. 18, 19 Another study showed that metabolic changes triggered by ASNase play an important role in determining leukemia cell fate. 20 However, to date, a therapeutically beneficial role of ASNase and its underlying mechanism for potentiating myeloid differentiation in AML cells have not been studied.
In an earlier study, we reported that Asn synthetase (ASNS), which controls the intracellular level of Asn by controlling the synthesis of this amino acid, was downregulated in HL-60 cells undergoing myeloid differentiation. 21 This finding correlates with the observations that have been reported by other research groups. 22, 23 In addition, another study reported that in culture medium that was deficient in individual essential amino acids, HL-60 cells underwent differentiation toward monocyte. 24 Together with previous reports, we proposed that amino acid-associated metabolism plays a pivotal role in multiple cellular processes, and that, conversely, its targeting by ASNase have a therapeutic effect on differentiation-responsive AML therapy. In this study, we tested whether the amino acid deprivation by ASNase shows in vitro and in vivo cooperative effects on the VD3-induced myeloid differentiation of AML cells. This approach provides a novel therapeutic insight into AML therapy.
Materials and Methods

Cell lines and reagents
Human HL-60 and THP-1 leukemia cell lines were obtained from Korean Cell Line Bank (KCLB, Seoul, Korea) and cultured in RPMI1640 medium (Corning, Manassas, VA) supplemented with 10% heat-inactivated fetal bovine serum (FBS, Capricorn, Ebsdorfergrund, Germany) and 100 IU/ml penicillin and 100 lg/ml streptomycin (Corning). OCI-AML-2 cells (DSMZ, Braunschweig, Germany) were grown in a-MEM (Gibco, Grand Island, NY) containing antibiotics and FBS. To maintain exponential growth, cells were seeded at a concentration of 1 3 10 5 cells/ml and subcultured every 3 days. ASNase derived from Escherichia coli was from Aviva Systems Biology (San Diego, CA) or Source Bioscience (Nottingham, UK) and reconstituted in phosphate-buffered saline (PBS) buffer. Glutaminase from E. coli was purchased from Megazyme (Wicklow, Ireland). VD3 (Tocris, Bristol, UK) was dissolved in ethanol and kept at 2808C until use. 10058-F4 (Sigma, St. Louis, MO) was dissolved in dimethyl sulfoxide. Phycoerythrin (PE)-conjugated human CD11b (BD Pharmingen, San Jose, CA) and allophycocyanin (APC)-conjugated human CD14 (eBiosciences, San Jose, CA) monoclonal antibodies were used for flow cytometric analysis. Nitroblue tetrazolium (NBT) and fluorescein isothiocyanate (FITC)-conjugated dextran were from USB (Cleveland, OH) and Sigma, respectively. Antibodies for c-Myc, phospho-4EBP1 (Ser65), GAPDH (SantaCruz, Santa Cruz, CA), LC3B, and b-catenin (Cell Signaling, Danvers, MA) were used for Western blot analyses. Other reagents were prepared as described elsewhere.
What's new?
A new combination could help take down acute myeloid leukemia. VD3, a hormonally active form of vitamin D, can induce terminal differentiation in AML cells, but its nasty side effects prevent it from being a useful treatment. In this article, the authors tested whether amino acid deprivation with L-asparaginase could help VD3 attack AML more efficiently. They found that giving L-asparaginase to tumor-bearing mice along with the VD3 enhanced AML differentiation and improved the mice's survival time, suggesting that it could be very effective in AML treatment.
Evaluation of leukemia cell differentiation
Cell differentiation was majorly evaluated by flow cytometric measurement of cell surface markers. Briefly, cells were washed with ice-cold PBS and labeled with fluorescent dyeconjugated monoclonal antibodies specific to human CD11b and CD14 in binding buffer (PBS containing 0.5% FBS and 0.1% sodium azide) at room temperature for 15 min. Resulting intensity was analyzed using BD FACSCalibur. Specific binding of the antibodies was confirmed by using isotype control antibodies. Morphologic change of cells was acquired by staining with Wright-Giemsa solution (Sigma), according to the previous report. 25 For NBT reduction assay, cells were collected and allowed to form a blue-black formazan for 30 min in PBS buffer containing NBT (0.1% w/v) and PMA (200 ng/ml, Sigma). Cells containing a crystal formazan were counted on a hemocytometer under a light microscope. At least 200 cells were accessed for each sample, and the result was expressed as a percentage of NBT-positive cells relative to total cells.
Antigen uptake assay
Antigen uptake assay was performed according to previous report with a slight modification. 26 Briefly, cells were collected and resuspended in complete medium supplemented with FITCconjugated dextran (0.5 mg/ml, Sigma) and PMA (200 ng/ml), followed by further incubation for 1 h. The cells were washed with PBS and their fluorescent intensity was determined by flow cytometry.
Determination of apoptotic cell death
Apoptotic cell death was analyzed by annexin-V/PI staining kit (Biobud, Sungnam, Korea). Briefly, cells were corrected and washed with ice-cold binding buffer. The cells were stained in the binding buffer containing FITC-conjugated annexin-V. The cells were further stained with PI and immediately applied to flow cytometry.
shRNA-based knockdown of c-myc
Recombinant lentiviral particles containing pLKO.1-puro control and c-myc shRNA (Clone ID, TRCN0000353004) were purchased from Sigma. Sequence of the shRNA targeting c-myc is the following: 5 0 -actcggtgcagccgtatttfct-3 0 . HL-60 cells were plated at 3 3 10 5 /ml and transduced with 10 ll of either c-myc shRNA-containing or control viral particles for 24 h. Afterward, the cells were cultured for 2 weeks in the presence of puromycin (0.2 lg/ml, Sigma). Knockdown efficacy was evaluated by reverse transcription-polymerase chain reaction and Western blotting. The stable cell lines, HL-60/ shCtrl and HL-60/shcMyc were maintained with 0.1 lg/ml puromycin.
Western blot analysis
Whole cell extracts were prepared in radioimmunoprecipitation buffer (RIPA; 50 mM Tris-Cl, 150 mM NaCl, 0.25% Na-deoxycholate, 1% NP40) supplemented with protease inhibitor cocktail. Equal amount of cell lysates were separated in 8-15% SDS-PAGE and transferred onto nitrocellulose or polyvinylidene difluoride membranes (GE healthcare, Munich, Germany). The membranes were incubated in blocking buffer (Tris-buffered saline containing 0.1% Tween-20 and 5% nonfat milk) and sequentially probed with primary antibodies (1:1,000) and horseradish peroxidase (HRP)-conjugated secondary antibodies (1:2,000-1:10,000). The immunobands were detected using ECL Western blotting detection reagents (GE healthcare, Buckinghamshire, UK) and LAS3000 image analyzer (FujiFilm, Japan). GAPDH was used as a loading control. The relative expression of proteins was quantified by densitometric analysis with Image J software and normalized relative to GAPDH expression.
Reverse transcription-polymerase chain reaction (RT-PCR) analysis
Total RNA from cells was isolated by the RiboEx TM reagent (GeneAll, Seoul, Korea). One and a half micrograms of RNA was converted to cDNA using the RocketScript RT kit (Bioneer, Daejeon, Korea). One microliter from each RT product was amplified by PCR with the following primer sets: c-myc
0 -cctccacgcacttcatcatc-3 0 ), and b-actin (forward, 5 0 -agcgggaaatcgtgcgtg-3 0 ; reverse, 5 0 -cagggtacatggtggtgcc-3 0 ). PCR products were analyzed by an agarose gel electrophoresis. Using Image J software, mRNA expression values were normalized to GAPDH and expressed relative to untreated group.
Fluorescence microscopic analysis
Cells were incubated in annexin-V-binding buffer with FITCconjugated annexin-V and PE-conjugated anti-CD11b antibody for 30 min, followed by the fixation with 4% paraformaldehyde. The cells were then permeabilized in 0.005% sodium dodecyl sulfate-containing binding buffer and further labeled with 1 lg/ml DAPI for 5 min. Final images were obtained using a fluorescence microscopy (Olympus IX71) and RSImage software.
In vivo experiments
Ten-to eleven-week-old female Balb/c nude mice were obtained from OrientBio (Seongnam, Korea). Animal experiments were performed in the animal facility of Korea University in accordance with the guidelines of Korea University Institutional Animal Care and Use Committee. HL-60 xenograft mouse model was established, according to the previous reports with slight modification. 27, 28 Briefly, mice were injected intraperitoneally with 3 mg cyclophosphamide/mouse to improve tumor take. After 3 days of the pretreatment, the mice were inoculated intraperitoneally with 3 3 10 7 HL-60 cells suspended in 150 ll sterile PBS. In a preliminary experiment with this protocol, we confirmed that HL-60 cells could grow in peritoneal cavity and mice died within 40 days without any treatment. One day after HL-60 cell inoculation, animals were randomly assigned into four treatment groups as follows: control (0.8% ethanol in PBS, n 5 7), ASNase alone (1,000 IU/kg, n 5 6), VD3 alone (25 lg/kg, n 5 6) and VD3 plus ASNase (n 5 6). All the above treatments were intraperitoneally administered every other day (3 times per week) for 3 weeks. Body weight and survival were monitored for 4 and 13 weeks, respectively. Overall survival was estimated by the Kaplan-Meier method with a log-rank test (SPSS Statistics 23.0).
Statistical analysis
Results were obtained from at least three independent experiments. Statistical significance of the difference between each group was determined using a paired Student's t test. A p value <0.05 was considered statistically significant.
Results
ASNase promotes VD3-induced myeloid differentiation
First, to examine an effect of ASNase-mediated amino acid deprivation on VD3-mediated monocyte/macrophage differentiation, we treated HL-60 cells (FAB M2) with ASNase in combination with a low dose (5 nM) of VD3. ASNase strongly enhanced the VD3-induced cell surface expression of differentiation markers, CD11b and CD14, in a concentration-dependent manner ( HL-60 cell differentiation. Furthermore, in a time kinetic study, VD3 combined with ASNase significantly improved the differentiation rate in HL-60 cells, compared with that of cells treated with VD3 alone (Fig. 1c) . Using NBT reduction assay and Wright-Giemsa staining, we also confirmed that VD3-induced generation of reactive oxygen species and morphological changes, such as a reduced nucleus to cytoplasmic ratio and a substantial segmented nucleus, were intensified by co-treatment of ASNase (Figs. 1d and 1e) . We further measured the functional maturation of AML cells based on their ability to uptake antigen using dextran uptake assay. A similar increase in antigen uptake ability was observed in the cells treated with VD3 and ASNase (Fig. 1f) . The cellular event accompanied by cell differentiation is likely correlated with the arrest of cell proliferation. To demonstrate a fundamental mechanism of the enhancing effect of ASNase on VD3-induced myeloid differentiation, cell cycle and viability were analyzed. Treatment with VD3 alone showed a weak induction of cell arrest at G1 phase, and the co-treatment with ASNase significantly augmented the cell population at G1 phase by VD3, along with significantly reduced cell distribution at S and G2/M phases (Supporting Information, Fig. 2b ). In addition, the levels of cell viability were the lowest in the cells cultured with VD3 plus ASNase (Supporting Information, Fig.  2c ), suggesting a possible contribution of cell growth inhibition to the enhanced cell differentiation by ASNase. These results suggest that ASNase-mediated deprivation of amino acid(s) increases the sensitivity of HL-60 cells to VD3. To validate whether the ASNase effect on myeloid differentiation is applicable to other AML cell types as well as HL-60 cell system, we additionally tested the ability of ASNase in two other AML cell-lines, OCI-AML-2 (FAB M4) and THP-1 (FAB M5). Similar to HL-60 cells, both cell lines were more sensitive to VD3 in the presence of ASNase, as determined by the enhanced markers expression (Fig. 1g and Supporting  Information, Fig. 3a) . These results indicate that the potential of ASNase to improve VD3 activity on the cell differentiation can be similarly applied to a broad range of AML cell lines.
c-Myc downregulation is crucial for ASNase-mediated sensitization of AML cells to VD3
Recent report has shown that the treatment with ASNase decreased c-Myc level in leukemia cells. 20 Additionally, there are considerable studies that support a central role for c-Myc in cell cycle regulation and differentiation. 29, 30 Given the apparent association of ASNase with c-Myc as a determinant of cell fate, we hypothesized that ASNase-mediated c-Myc downregulation is crucial for the susceptibility of AML cells to VD3. First, the combinatorial effect of ASNase and VD3 on c-Myc expression was tested in HL-60 cells. As shown in Figures 2a and 2b , consistent with the previous report, ASNase treatment decreased c-Myc protein and mRNA levels, whereas treatment with VD3 alone little affected protein level only. 20 Interestingly, we found that co-treatment with both drugs accelerated the downregulation of c-Myc protein and mRNA. Similar effect of ASNase on c-Myc expression was reproduced in other AML cell lines, OCI-AML-2 and THP-1 ( Supporting Information, Fig. 3b ). As c-Myc has been previously shown to be regulated by Wnt/b-catenin signaling, 31 we further investigated the expression of b-catenin. As expected, the combined treatment with VD3 and ASNase as well as the treatment with ASNase alone resulted in the reduction of b-catenin expression level (Fig. 2a) . Next, in RT-PCR analysis for genes encoding proteins involved in energy metabolism, ASNase downregulated GLUT1 and LDHA, and the combination treatment further downregulated their expression (Fig. 2b) . These data suggest that ASNasemediated c-Myc downregulation is associated with the enhancement of VD3-triggered myeloid differentiation.
To demonstrate the role of c-Myc in the differentiation, HL-60 cells were treated with VD3, together with 10058-F4, a chemical inhibitor of c-Myc. Cells that were treated with VD3 and 10058-F4 showed >70% increase in CD11b and CD14 double positive cells, when compared to that in cells treated with only VD3 (Fig. 2c) . We further confirmed the significance of c-Myc expression levels in the differentiation by utilizing a lentiviral shRNA delivery system. As shown in Figure 2d and Supporting Information, Figure 4a , silencing c-Myc significantly increased VD3 sensitivity in HL-60 cells. Furthermore, we observed that the cells infected with shRNA for c-Myc had the altered gene expression of cell cycle regulators, p21 and cdk2, and decreased cell viability, compared with those of the cells infected with control shRNA, suggesting a defect in the rapid cell growth (Supporting Information, Figs. 4b and 4c) . Given the requirement for c-Myc downregulation to maximize the induction of AML cell differentiation, we further determined an optimal treatment condition of ASNase, in aspect of therapeutic use. When the cells were treated according to the treatment schedules as described in Figure 2e , we found that pretreatment with ASNase prior to the treatment with VD3 plus ASNase was the most effective on myeloid differentiation. Collectively, these results suggest that c-Myc is the main target of ASNase and that ASNase-mediated downregulation of c-Myc is crucial to improve VD3 efficacy.
ASNase intensified VD3 regulation of mTORC1 signaling and autophagy during myeloid differentiation
Amino acid deprivation due to ASNase treatment inhibits mTORC1 signaling, resulting in the induction of autophagy. [18] [19] [20] 32 Other group reported that autophagy is caused in AML cells undergoing myeloid differentiation by VD3, and that blocking autophagy by silencing beclin1 attenuates cell sensitivity to VD3-induced differentiation. 33 These reports raised a possibility that mTORC1 inhibition and autophagy induction triggered by VD3 are augmented by addition of ASNase, leading to the enhancement of AML cell differentiation. To address the question, we treated cells with VD3, ASNase or both, and performed Western blotting (Fig. 3a) . Treatment with each agent alone inhibited the phosphorylation of 4EBP1, a well-known downstream target of mTORC1, and this event was significantly enhanced when the treatments were combined. To investigate whether each culture condition induces autophagic flux, we detected the accumulation of an autophagosome marker, LC3-II. As expected, cotreatment with VD3 and ASNase accelerated LC3-II expression, as determined by Western blot analysis (Fig. 3a) . Similarly, the alterations of these molecules by ASNase were also observed in OCI-AML-2 and THP-1 cell-lines ( Supporting  Information, Fig. 3b ). The alteration of LC3-II accumulation following the treatment with either VD3 alone or VD3 plus ASNase was intensified by treatment with CQ, an inhibitor of fusion of autophagosome with lysosome (Fig. 3b) , indicating that the observed increase in LC3-II after the treatment was due to increased autophagic flux rather than decreased degradation of lipidated LC3. Given the obvious alteration in the expression of p-4EBP1 and LC3-II, we further investigated an involvement of mTORC1 signaling in the enhanced differentiation by using rapamycin (RAPA), an inhibitor of mTORC1 signaling. Although the margin of increase in cell differentiation was not remarkable, RAPA-induced hypoactivation of mTORC1 pathway enhanced the ability of VD3 to induce myeloid differentiation (Supporting Information, Fig. 5 ). Collectively, these data showed that the suppression of mTORC1 and the induction of autophagy by treating with ASNase may contribute to the enhancement of VD3-mediated AML cell differentiation. 33 To further address the cross-talk between c-Myc and mTORC1 signaling, we treated HL-60 cells with VD3 plus ASNase, RAPA and 10058-F4 for 24 h, and then compared the protein levels for c-Myc and p-4EBP1. When compared to the untreated control, cells treated with either VD3 plus ASNase or with 10058-F4 showed decreased levels of both proteins; however, RAPA-treated cells showed decreased level of p-4EBP1 only (Fig. 3d) . Additionally, we found that phosphorylation level of 4EBP1 in HL-60/shcMyc cells was lower than that in HL-60/shCtrl cells (Fig. 3e) . These results suggested that c-Myc inhibition following treatment with VD3 and ASNase results in mTORC1 inhibition, but the mechanism underlysing c-Myc inhibition is independent of mTORC1 pathway. 
Glutaminase activity of ASNase is also important for the enhanced cell differentiation
ASNase has two different deamidation activities, that is, asparaginase and glutaminase. 34 We used a commercially obtained GLNase to determine the individual role of dual activities of ASNase on the enhanced myeloid differentiation, although the use of GLNase under clinical settings has been restricted due to severe side effects, including pancreatitis and thrombosis. 35 Similar to ASNase, GLNase alone had no effect on the differentiation, but, when combined with VD3, GLNase strongly promoted VD3 effect in a similar degree of phenotypical and functional differentiation in a concentration-dependent manner, as confirmed by the cell surface marker expression, NBT reduction activity and cellular morphologic change (Fig. 4a and Supporting Information, Fig. 6 ). We next looked to determine whether GLNase also has a property to downregulate c-Myc and mTORC1 signaling as the mechanism for enhancing VD3-induced AML differentiation. As determined by Western blot analysis, VD3-mediated alterations of c-Myc, p-4EBP1 and LC3-II proteins were more intensified when VD3 treatment was combined with GLNase (Fig. 4b) . These results reflect a significance of GLNase activity, one of the dual activities of ASNase, in the augmentation of VD3-induced myeloid differentiation.
Sustained VD3 efficacy by the combined treatment with ASNase
The recurrent propagation of AML cells that escape terminal differentiation is one of the main obstacles to complete remission. Therefore, we evaluated the ability of ASNase to sustain the antileukemic effect of VD3. HL-60 cells were cultured for 72 h in normal culture media, or in culture media containing ASNase (0.2 IU/ml) alone, VD3 (100 nM) alone or both. At the end of incubation, each culture was collected and further cultured in complete medium without drugs. During 5 days of postculture, we monitored the changes of cellular events, including differentiation, growth and apoptotic cell death. As shown in Figure 5a and Supporting Information, Figure 7a , CD11b and CD14 double-positive populations generated by the treatment with either VD3 alone or VD3 plus ASNase at the beginning of postculture were 79% and 90%, respectively. Notably, on Day 5 of the postculture, 35% of the population generated by treatment with VD3 plus ASNase still remained positive to both markers, while only 8% of VD3-driven differentiated cells remained positive. In the NBT reduction assay, like the change of cell surface marker expression, a continuous functional differentiation was observed in the cells treated with VD3 plus ASNase, compared to those cells treated with VD3 alone (Fig. 5b) . Additionally, a large number of cells had monocyte/macrophagocyte-like cellular morphologies ( Supporting  Information, Fig. 7b ). In a parallel examination for cell growth, we found that the cells treated with either ASNase or VD3 rapidly propagated after 3 days of postculture, while the cells treated with both drugs did little even at Day 5 of postculture (Fig. 5c) . We also noted distinguished patterns of apoptotic cell death in cells cultured under each of the four different conditions. Interestingly, the population of annexin-V-positive cells dramatically increased after 3 days of postculture in the cells treated with VD3 plus ASNase, whereas those in cells treated with VD3 alone increased slightly (Fig. 5d) . Apoptotic cell death in ASNase-treated cells was high at early times, but rapidly diminished over the culturing period. In addition, using immunocytochemistry analysis, we demonstrated that apoptosis in the cells treated with VD3 plus ASNase existed preferentially in cells with CD11b expression, indicating a differentiation-related cell death (Fig. 5e) .
Last, to evaluate in vivo antitumor effects of VD3 and ASNase, nude mice were inoculated intraperitoneally with HL-60 cells for a survival study. As shown in Kaplan-Meier survival analysis of Figure 6a , administration of either ASNase at a dosage of 1,000 IU/kg (3 times per week for 3 weeks, p < 0.05 vs vehicle control group) or VD3 at a dosage of 25 lg/kg (3 times per week for 3 weeks, p < 0.05 vs vehicle control group) showed slight increase of survival time in mice that was statistically significant relative to vehicle treatment. Importantly, the survival rate increased by administration of VD3 alone was significantly prolonged when ASNase was combined (p < 0.005 vs vehicle control group, p < 0.05 vs VD3 group). Administration of either VD3 alone or VD3 plus ASNase resulted in body weight loss in mice, but this symptom was rapidly recovered by discontinuing drug inoculation (Fig. 6b) . These results suggest that the combination of VD3 and ASNase provides a novel strategy for differentiationinducing chemotherapy of AML.
Discussion
Although there has been clinical progress in the treatment of AML over the past decades, the current therapy is poorly effective for some patients, most probably because of the consistent use of classical standard chemoregimens. 1 To solve the problems endemic in AML, growing interests have focused on the extended application of differentiation induction therapy, which is efficaciously applied to APL. Our study shows, for the first time, that the depletion of extracelluar Asn and Gln by ASNase treatment strongly enhances the VD3-induced differentiation of AML cells into monocyte/ macrophage, mostly through downregulation of c-Myc, and that treatment with this enzyme leads to differentiationinduced apoptotic cell death. c-Myc is a multifunctional transcription factor that is involved in cell cycle, apoptosis and cellular differentiation. In cancer cells, aberrant c-Myc expression is transcriptionally regulated by extracellular oncogenic stimulus, such as growth factors. On the other hand, another report showed that the c-Myc protein level is closely related to its instability, which is controlled by proteasomal degradation. 36 In this study, we observed that treatment with ASNase alone, or in combination with VD3, inhibited the expression of c-Myc mRNA and protein. This result indicates that the ASNase-mediated decrease in c-Myc expression is regulated by inhibition of an upstream oncogenic signal rather than by posttranslational instability. However, in HL-60 cells, the suppressive effect of VD3, which led to the slight decrease of c-Myc protein, was not observed at mRNA level. In contrast with the regulation of c-Myc protein by ASNase, this discordant result suggests that VD3 may control c-Myc expression at the posttranslational stage. Our explanation is supported by the recent report that a half-life of c-Myc protein can be also shortened by VD3. 37 It has been widely accepted that leukemic cells, as well as solid tumor cells, have distinct metabolic profiles. 38, 39 Notably, elevated glycolysis is the main route for generating energy to support the rapid proliferation of cancer cells. Because of a distinctive feature of cancer cells, several reports demonstrated that controlling energy metabolism by ASNase influences AML cell fate. 19, 20 Recently, another article reported that chemical inhibition of c-Myc by 10058-F4 induces neuroblastoma differentiation through the reprogramming of a broad range of metabolism-related genes. 40 In this study, we detected reduced level of genes that encode an enzyme (LDHA) and the glucose transporter (GLUT1) involved in active glycolysis, along with downregulation of c-Myc following ASNase treatment, and that these events were enhanced when ASNase treatment was combined with VD3. Additionally, despite the use of ASNase at nontoxic concentration (0.2 IU/ml), we detected gradually increasing apoptosis in fully differentiated cells treated with both VD3 and ASNase. Although the role of energy metabolism on AML differentiation is still undefined, our results suggest that, at least in part, the ASNase-mediated change in glycolytic metabolism contributes to both VD3-driven myeloid differentiation and subsequent apoptotic cell death in AML cells.
Another interesting finding is that the expression levels for GLUT1 and LDHA but not of CS and SLC1A5 were downregulated by treatment with either ASNase alone or VD3 and ASNase together, although their levels were analyzed by RT-PCR only. GLUT1 and LDHA play a central role in glycolysis during energy metabolism, whereas SLC1A5 and CS play roles in glutaminolysis. 41 Therefore, our results suggest that the enhanced myeloid differentiation following ASNase treatment largely relies on a defect in glucose metabolism rather than the disruption of glutaminolysis. However, the distinctive effect of ASNase on the expression of these genes needs to be further examined because they are all considered as representative downstream targets of c-Myc. 40, 41 ASNase has dual activities: it is an asparaginase and a glutaminase. In this study, to determine which of the activities is more closely involved in the enhanced myeloid differentiation, we used commercially available GLNase. Intriguingly, GLNase also had a significant combinatorial effect on the VD3-induced differentiation of AML cells. However, to produce an effect that was equivalent to that of ASNase, a 10-fold higher concentration of GLNase was required, suggesting that asparaginase activity is more crucial for the enhancement of VD3-induced differentiation. Additionally, the enhancing effect of ASNase on AML differentiation began even at 24 h after ASNase treatment in a time-kinetic study, as shown in Figure  1c . The length of treatment with ASNase appears to be sufficient to completely remove extracellular Asn, but not Gln, suggesting a preference for the asparaginase activity. 19 Understating the precise role of the ASNase activity is crucial for therapeutically extended clinical application of this enzyme because of the known side effects, which are most likely caused by the glutaminase activity. The effects of the glutaminase activity can be fully addressed by using recombinant ASNase with mutation at critical sites, as previously described elsewhere. 34 Although our efforts to study the influence of each of the activities of ASNase were insufficient to make a conclusion, our results imply that the removal of either Asn or Gln is sufficient to improve VD3 efficacy.
Many studies that have developed new approaches to assist the application of differentiation-inducing agents in non-APL AML therapy have to solve their current limitations, including concerns about their safety and therapeutic efficacy in the clinic. ASNase was approved for cancer treatment by the Food and Drug Administration (FDA), and three different types of ASNase (i.e., Elspar, Crisantaspase and PEGylated Lasparaginase) are available. ASNase has been indicated as an essential drug for ALL, and this enzyme has the potential to improve the anticancer efficacy when used in combination with other drugs. 42 As part of these trials, we explored a novel effect of ASNase on AML induction therapy. In this study, we showed that the combinatorial activity of ASNase together with VD3 was effective to not only in vitro AML cells but also in vivo human xenograft model. Notably, as demonstrated in Figure  6b , no detectable change in body weight was observed in vivo study. Therefore, we propose that ASNase has a strong advantage over either other chemostatic drugs or newly developed compounds because of its minor side effects. Our proposal is supported by the facts that ASNase has been well tolerated by patients with ALL since 1970s.
Overall, our data demonstrate the therapeutically beneficial role of ASNase-mediated depletion of amino acids for enhancing non-APL VD3-mediated AML differentiation, and they show that targeting c-Myc and metabolic processes by treatment with VD3 plus ASNase may be a novel approach for AML.
